Latest On Ipsen S.A (IPSEF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-06-02 06:02 EST | Dividend | A dividend of $1.2 has been announced on Apr 7, 2023. It will be paid Jun 6, 2023 with an ex-dividend date of Jun 2, 2023. | Neutral |  |
| 2023-03-17 03:21 EST | News | New FDA action date in August for Ipsen bone disease drug palovarotene | N/A | |
| 2023-02-09 19:25 EST | News | Ipsen S.A. (IPSEY) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-09 05:28 EST | News | Ipsen S.A. Non-GAAP EPS of €10.51, revenue of €3.02B; initiates FY23 guidance | N/A | |
| 2023-02-02 13:03 EST | News | Buyout From Ipsen: Do Not Underestimate The Value Of Albireo's Contingent Value Right | N/A | |
| 2023-01-27 16:45 EST | News | Ipsen faces another setback for bone disorder drug with EMA panel's rejection | N/A | |
| 2023-01-20 13:17 EST | News | Ipsen presents full data showing 'survival benefit' in pancreatic cancer in phase 3 trial | N/A | |
| 2023-01-09 11:07 EST | News | Albireo stock jumps 85% as Ipsen set to acquire it for ~$952M | N/A | |
| 2022-12-27 16:08 EST | News | Ipsen says FDA rejected treatment for rare bone disorder | N/A | |
| 2022-11-09 17:24 EST | News | Ipsen Onivyde combo meets trial's survival goal in untreated pancreatic cancer patients | N/A | |
| 2022-11-09 17:24 EST | News | Merrimack jumps 183% as partner Ipsen says pancreatic cancer trial met main goal | N/A | |
| 2022-11-02 10:47 EST | News | Ipsen S.A. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-10-27 19:01 EST | News | Ipsen S.A. reports Q3 results; reaffirms FY22 guidance | N/A | |
| 2022-08-05 12:03 EST | News | Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance, required shares | N/A | |
| 2022-08-03 14:56 EST | News | Ipsen Onivyde fails to improve overall survival of lung cancer patients in phase 3 trial | N/A | |
| 2022-08-01 19:47 EST | News | Ipsen to pay $45M upfront to advance Marengo's 2 immuno-oncology candidates | N/A | |
| 2022-07-30 11:56 EST | News | Ipsen S.A.'s (IPSEY) CEO David Loew on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-28 18:09 EST | News | Ipsen S.A. 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-06-29 08:51 EST | News | Ipsen's rare bone/tissue disorder drug gets FDA priority review | N/A | |
| 2022-06-27 20:44 EST | News | Epizyme stock soars 60% as Ipsen set to acquire the cancer drugmaker | N/A | |
| 2022-06-10 07:59 EST | News | Ipsen gets positive opinion in Europe for bladder loss control drug Dysport | N/A | |
| 2022-05-31 06:02 EST | Dividend | A dividend of $1.2 has been announced on Feb 11, 2022. It will be paid Jun 2, 2022 with an ex-dividend date of May 31, 2022. | Neutral | |
| 2022-05-03 06:45 EST | News | Ipsen, Exelixis' Cabometyx gets approval in EU to treat thyroid cancer subtype | N/A | |
| 2022-04-27 15:55 EST | News | Ipsen S.A. reports Q1 results | N/A | |
| 2022-03-26 21:02 EST | News | Ipsen, Exelixis' Cabometyx gets EMA panel nod for expanded use in thyroid cancer | N/A | |
| 2022-03-16 20:11 EST | News | Ipsen to invest ~€60M in 4th gen autoinjector Somatuline, Signes manufacturing site | N/A | |
| 2022-03-09 00:11 EST | News | Ipsen's data shows patient benefit when using Somatuline | N/A | |
| 2022-03-03 05:00 EST | News | Ipsen/Exelixis, Bristol-Myers' drug combo shows survival benefits in kidney cancer | N/A | |
| 2022-02-15 15:33 EST | News | Exelixis/Bristol-Myers' drug combo shows sustained survival benefits in kidney cancer | N/A | |
| 2022-02-14 20:15 EST | News | Ipsen S.A. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-02-12 08:58 EST | News | Ipsen S.A. (IPSEY) CEO David Loew on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-11 13:47 EST | News | Ipsen S.A. GAAP EPS of €7.76, revenue of €3B | N/A | |
| 2021-12-17 15:24 EST | News | Genfit inks licensing deal for elafibranor with Ipsen | N/A | |
| 2021-10-21 22:34 EST | News | Ipsen reports Q3 results, boosts it full year guidance | N/A | |
| 2021-09-25 14:57 EST | News | Ipsen S.A. (IPSEY) Investor Presentation - Slideshow | N/A | |
| 2021-08-02 09:11 EST | News | Ipsen S.A. (IPSEY) CEO Francesco Caio on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-31 01:56 EST | News | Ipsen S.A. 2021 Q1 - Results - Earnings Call Presentation | N/A | |
| 2021-05-28 06:08 EST | Dividend | A dividend of $1 has been announced on Feb 11, 2021. It will be paid Jun 2, 2021 with an ex-dividend date of May 28, 2021. | Neutral | |
| 2021-04-02 03:53 EST | News | Fusion closes acquisition of IPN-1087 from Ipsen | N/A | |
| 2021-02-17 13:00 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-12 11:25 EST | News | Ipsen S.A. (IPSEY) CEO David Loew on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-10 23:53 EST | News | Bristol Myers announce new late-stage data for Opdivo/ Cabometyx combo in kidney cancer | N/A | |
| 2020-11-26 23:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-21 08:53 EST | News | BMY/Exelixis Opdivo + Cabometyx shows survival benefits in late-stage kidney cancer study | N/A | |
| 2020-09-17 07:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:07 EST | Financials | Company financials have been released. | Neutral | |
About Ipsen S.A (IPSEF):
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company offers drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, and Mucodyne. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
General
- Name Ipsen S.A
- Symbol IPSEF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 5,700
- Fiscal Year EndDecember
- Web URLhttp://www.ipsen.com
Valuation
- Trailing PE 21.44
- Forward PE 12
- Price/Sales (Trailing 12 Mt.) 2.66
- Price/Book (Most Recent Quarter) 3.85
- Enterprise Value Revenue 2.3
- Enterprise Value EBITDA 7.8
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 20%
- Return on Assets 10%
- Return on Equity 28%
- Revenue Per Share $0
- Gross Profit 2.2 billion
- Quarterly Earnings Growth -1.5%
ESG Rating
Highlights
- Market Capitalization 6.58 billion
Share Statistics
- Shares Outstanding 82.74 million
- Shares Float 34.82 million
- % Held by Insiders 5714%
- % Held by Institutions 21.2%
Technicals
- Beta 0.91
- 52 Week High $102.45
- 52 Week Low $54.94
- 50 Day Moving Average 102.45
- 200 Day Moving Average 102.45
Dividends
- Forward Annual Dividend Rate $1.13
- Forward Annual Dividend Yield 1.11%
- Payout Ratio 16%
- Dividend Date N/A
- ExDividend Date 2020-06-03
- Dividend Per Share $1.13
- Dividend Yield 0%
Ipsen S.A (IPSEF) Dividend Calendar:
Ipsen S.A pays out 16% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Ipsen S.A (IPSEF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $2.37 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $2.28 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $1.49 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $699.95 million | $1.46 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $699.95 million | -$1.83 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $729.55 million | -$1.78 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $724.88 million | $1.47 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $701.59 million | $1.45 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $708.09 million | $1.30 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $562.55 million | $1.32 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $562.55 million | $1.39 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $521.05 million | $1.47 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $521.05 million | $1.05 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $484.85 million | $1.03 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $484.85 million | $0.86 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $432.25 million | $0.80 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $432.25 million | $0.59 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $0.63 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.90 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.92 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.65 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.67 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.61 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.58 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.36 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.38 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.87 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.87 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.43 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.42 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.70 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.69 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.75 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.80 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.15 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.15 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.79 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.77 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.16 | $0.00 |
Ipsen S.A (IPSEF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 106.25 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -159.6 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 264.95 million |
| Gross Profit | N/A | N/A | N/A | N/A | 574.4 million |
| Ebit | N/A | N/A | N/A | N/A | 168.1 million |
| Operating Income | N/A | N/A | N/A | N/A | 168.1 million |
| Income Tax Expense | -32.65 million | -32.65 million | 23.75 million | 23.75 million | -24.15 million |
| Total Revenue | N/A | N/A | N/A | N/A | 699.95 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 125.55 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -327.7 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -135.45 million |
| Net Income Applicable to Common Shares | 163.05 million | 163.05 million | 110.95 million | 110.95 million | -135.4 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -5.3 million | -5.3 million | N/A |
| Change to Liabilities | -13.9 million | -13.9 million | 50.15 million | 50.15 million | -1.07 million |
| Total Cash Flow from Investing Activities | -33.15 million | -33.15 million | -83.25 million | -83.25 million | -559.08 million |
| Net Borrowings | -25.35 million | -25.35 million | -53.65 million | -53.65 million | 423.6 million |
| Total Cash Flow from Financial Activities | N/A | N/A | -56.25 million | -56.25 million | 373.83 million |
| Change to Operating Activities | -20.95 million | -20.95 million | 21.45 million | 21.45 million | -25.79 million |
| Change in Cash | N/A | N/A | 79 million | 79 million | -73.3 million |
| Total Cash from Operating Activities | 146.8 million | 146.8 million | 217.5 million | 217.5 million | 108.73 million |
| Depreciation | N/A | N/A | 42.05 million | 42.05 million | 43.51 million |
| Other Cash Flow from Investing Activities | -5.75 million | -5.75 million | 12.6 million | 12.6 million | -42.15 million |
| Change to Inventory | N/A | N/A | -7.1 million | -7.1 million | -6.43 million |
| Change to Account Receivables | N/A | N/A | 4.45 million | 4.45 million | -50.11 million |
| Other Cash Flow from Financing Activities | -2.65 million | -2.65 million | 4.2 million | 4.2 million | -1.07 million |
| Change to Net Income | 8.05 million | 8.05 million | 233 million | 233 million | 17.32 million |
| Capital Expenditures | N/A | N/A | 34.25 million | 34.25 million | 42.88 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 2.55 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 1.75 billion |
| Other Current Liabilities | 715.1 million | 715.1 million | N/A | N/A | 329.6 million |
| Total Assets | N/A | N/A | N/A | N/A | 4.31 billion |
| Common Stock | 83.8 million | 83.8 million | 83.8 million | 83.8 million | 83.8 million |
| Other Current Assets | 113.7 million | 113.7 million | N/A | N/A | 132.1 million |
| Retained Earnings | 548 million | 548 million | 221.9 million | 221.9 million | -50.7 million |
| Other Liabilities | 982.4 million | 982.4 million | 243 million | 243 million | 246.7 million |
| Other Assets | 251.2 million | 251.2 million | 184.9 million | 184.9 million | 153.9 million |
| Cash | N/A | N/A | N/A | N/A | 353.3 million |
| Total Current Liabilities | 1.21 billion | 1.21 billion | N/A | N/A | 1.45 billion |
| Other Stockholder Equity | -59.6 million | -59.6 million | 24.3 million | 24.3 million | 61.8 million |
| Property, Plant & Equipment | 646.6 million | 646.6 million | 654.2 million | 654.2 million | 679.3 million |
| Total Current Assets | 1.58 billion | 1.58 billion | N/A | N/A | 1.35 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 111.4 million |
| Net Tangible Assets | 405.1 million | 405.1 million | -17.7 million | -17.7 million | -264.8 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 59.3 million |
| Long Term Debt | N/A | N/A | N/A | N/A | 854.7 million |
| Inventory | 213.9 million | 213.9 million | N/A | N/A | 214 million |
| Accounts Payable | 495.2 million | 495.2 million | N/A | N/A | 508.5 million |
Ipsen S.A (IPSEF) Chart:
Ipsen S.A (IPSEF) News:
Below you will find a list of latest news for Ipsen S.A (IPSEF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Ipsen S.A (IPSEF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Ipsen S.A (IPSEF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|